Inventor · disambiguated record
Samuel Davis
Also filed as: DAVIS SAMUEL · DAVIS SAMUEL A
66 granted patents·40 pending applications·2,504 citations·filing 1991–2025
99Inventor score
Files withREGENERON PHARMA91ILNP COSMETICS INC2PAPADOPOULOS NICHOLAS J2AMPLIFIED AI A DELAWARE CORP1BABB ROBERT1
Top patents by PatentIndex Score
106 records- 0199US10392430B2Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2017·Granted Aug 27, 2019·37 cites·2 claims
- 0299US9708386B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2015·Granted Jul 18, 2017·41 cites·5 claims
- 0399US8343737B2Cell culture compositions capable of producing a VEGF-binding fusion polypeptideREGENERON PHARMA·Filed 2011·Granted Jan 1, 2013·73 cites·12 claims
- 0499US8029791B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2008·Granted Oct 4, 2011·73 cites·9 claims
- 0599US7704500B2Methods of inhibiting ascites formation with modified chimeric VEGF polypeptidesREGENERON PHARMA·Filed 2008·Granted Apr 27, 2010·59 cites·8 claims
- 0699US7374757B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2004·Granted May 20, 2008·137 cites·7 claims
- 0799US7374758B2Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereofREGENERON PHARMA·Filed 2004·Granted May 20, 2008·124 cites·3 claims
- 0899US7205148B2Genome mutation by intron insertion into an embryonic stem cell genomeREGENERON PHARMA·Filed 2004·Granted Apr 17, 2007·93 cites·9 claims
- 0999US7070959B1Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2000·Granted Jul 4, 2006·196 cites·15 claims
- 1098US9139644B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2013·Granted Sep 22, 2015·44 cites·7 claims
- 1198US8647842B2Methods for producing a fusion protein capable of binding VEGFPAPADOPOULOS NICHOLAS J·Filed 2012·Granted Feb 11, 2014·79 cites·14 claims
- 1298US7964377B2Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGFREGENERON PHARMA·Filed 2008·Granted Jun 21, 2011·45 cites·8 claims
- 1398US7524499B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2008·Granted Apr 28, 2009·52 cites·3 claims
- 1497US9359437B2Antibodies comprising chimeric constant domainsREGENERON PHARMA·Filed 2014·Granted Jun 7, 2016·91 cites·21 claims
- 1597US8586713B2Readily isolated bispecific antibodies with native immunoglobulin formatDAVIS SAMUEL·Filed 2010·Granted Nov 19, 2013·422 cites·8 claims
- 1697US8084234B2Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGFPAPADOPOULOS NICHOLAS J·Filed 2010·Granted Dec 27, 2011·54 cites·13 claims
- 1796US12180272B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2022·Granted Dec 31, 2024·2 cites·11 claims
- 1896US11708407B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2022·Granted Jul 25, 2023·2 cites·26 claims
- 1996US10556952B2Heavy chain constant regions with reduced binding to Fc gamma receptorsREGENERON PHARMA·Filed 2016·Granted Feb 11, 2020·12 cites·24 claims
- 2095US11518807B2Heavy chain constant regions with reduced binding to Fc gamma receptorsREGENERON PHARMA·Filed 2019·Granted Dec 6, 2022·8 cites·40 claims
- 2195US10988537B2Antibodies comprising chimeric constant domainsREGENERON PHARMA·Filed 2018·Granted Apr 27, 2021·10 cites·20 claims
- 2295US6166185AAntibodies to human TIE-2 ligandsREGENERON PHARMA·Filed 1998·Granted Dec 26, 2000·142 cites·2 claims
- 2393US10550193B2Methods and antibody compositions for tumor treatmentREGENERON PHARMA·Filed 2015·Granted Feb 4, 2020·8 cites·32 claims
- 2493US5521073ATIE-2 ligand, and method of makingREGENERON PHARMA·Filed 1994·Granted May 28, 1996·116 cites·9 claims
- 2592US12391753B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Granted Aug 19, 2025·0 cites·22 claims
- 2692US11045522B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2018·Granted Jun 29, 2021·3 cites·5 claims
- 2792US5879672ATie-2 ligand 1REGENERON PHARMA·Filed 1994·Granted Mar 9, 1999·97 cites·16 claims
- 2892US5650490ATie-2 ligand 2REGENERON PHARMA·Filed 1995·Granted Jul 22, 1997·97 cites·8 claims
- 2991US12215148B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2020·Granted Feb 4, 2025·2 cites·25 claims
- 3091US2025333492A1Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3190US12509514B2Antibodies comprising chimeric constant domainsREGENERON PHARMA·Filed 2021·Granted Dec 30, 2025·1 cites·32 claims
- 3290US12331109B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Granted Jun 17, 2025·0 cites·23 claims
- 3390US11168111B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2018·Granted Nov 9, 2021·3 cites·24 claims
- 3490US10106610B2Antibodies comprising chimeric constant domainsREGENERON PHARMA·Filed 2016·Granted Oct 23, 2018·7 cites·24 claims
- 3590US7045302B2Expressed ligand-vascular intercellular signaling moleculeREGENERON PHARMA·Filed 2005·Granted May 16, 2006·10 cites·4 claims
- 3690US5814464ANucleic acids encoding TIE-2 ligand-2REGENERON PHARMA·Filed 1995·Granted Sep 29, 1998·67 cites·11 claims
- 3789US9982013B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2016·Granted May 29, 2018·3 cites·22 claims
- 3889US9309326B2Readily isolated bispecific antibodies with native immunoglobulin formatREGENERON PHARMA·Filed 2013·Granted Apr 12, 2016·5 cites·19 claims
- 3989US7063840B2TIE-2 ligands, methods of making and uses thereofREGENERON PHARMA·Filed 2002·Granted Jun 20, 2006·19 cites·11 claims
- 4089US5643755ANucleic acid encoding tie-2 ligandREGENERON PHARMA·Filed 1994·Granted Jul 1, 1997·72 cites·11 claims
- 4188US6441137B1Expressed ligand-vascular intercellular signalling moleculeREGENERON PHARMA·Filed 2000·Granted Aug 27, 2002·21 cites·5 claims
- 4287US12090193B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Granted Sep 17, 2024·0 cites·10 claims
- 4387US11965020B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2023·Granted Apr 23, 2024·0 cites·24 claims
- 4487US2025289883A1Novel antigen binding molecule formatsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4585US2025000949A1Glucagon-like peptide 1 receptor agonists and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4684US6825008B2Expressed ligand—vascular intercellular signalling moleculeREGENERON PHARMA·Filed 2002·Granted Nov 30, 2004·13 cites·7 claims
- 4782US12168681B2Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereofREGENERON PHARMA·Filed 2023·Granted Dec 17, 2024·0 cites·5 claims
- 4882US11434300B2Methods and antibody compositions for tumor treatmentREGENERON PHARMA·Filed 2019·Granted Sep 6, 2022·2 cites·20 claims
- 4982US2024156070A1Common light chain mouseREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 5081US12509516B2Heavy chain constant regions with reduced binding to Fc gamma receptorsREGENERON PHARMA·Filed 2022·Granted Dec 30, 2025·0 cites·19 claims
Showing the top 50 of 106 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Samuel Davis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →